Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
DENTSPLY SIRONA Inc Market Cap
The DENTSPLY SIRONA Inc (XRAY) share price is expected to increase by 21.08% over the next year. This is based on calculating the average 12-month share price estimate provided by 13 stock analysts who have covered XRAY. Price targets range from $28 at the low end to $36 at the high end. The current analyst consensus for XRAY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
DENTSPLY SIRONA Inc has a total of 13 Wall St Analyst ratings. There are 8 buy ratings, 4 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that DENTSPLY SIRONA Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of XRAY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Saxon Needham | Buy | $34 | Reiterates | Aug 20, 2024 |
| David Saxon Needham | Buy | $34 | Maintains | Jul 31, 2024 |
| Jeffrey Johnson Baird | Neutral | $31 | Maintains | Jul 22, 2024 |
| Jonathan Block Stifel | Hold | $28 | Maintains | Jul 18, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $27 | Maintains | Jul 9, 2024 |
| Michael Petusky Barrington Research | Outperform | $38 | Maintains | Jul 8, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $28 | Maintains | Jun 25, 2024 |
| Nathan Rich Goldman Sachs | Neutral | $30 | Maintains | May 6, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $35 | Maintains | May 3, 2024 |
| Jeffrey Johnson Baird | Neutral | $33 | Maintains | May 3, 2024 |
| David Saxon Needham | Buy | $36 | Maintains | May 3, 2024 |
| Jason Bednar Piper Sandler | Neutral | $32 | Reiterates | May 3, 2024 |
| Michael Petusky Barrington Research | Outperform | $38 | Maintains | May 3, 2024 |
| Michael Petusky Barrington Research | Outperform | $41 | Maintains | Apr 18, 2024 |
| Michael Petusky Barrington Research | Outperform | $41 | Reiterates | Mar 1, 2024 |
| David Saxon Needham | Buy | $42 | Reiterates | Feb 29, 2024 |
| Michael Cherny Leerink Partners | Outperform | $42 | Initiates | Feb 26, 2024 |
| Jason Bednar Piper Sandler | Neutral | $35 | Maintains | Jan 12, 2024 |
| David Saxon Needham | Buy | $42 | Maintains | Jan 9, 2024 |
| David Saxon Needham | Buy | $35 | Initiates | Nov 16, 2023 |
When did it IPO
1987
Staff Count
15,000
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Simon D. Campion
Market Cap
$5.15B
In 2023, XRAY generated $3.97B in revenue, which was a increase of 1.10% from the previous year. This can be seen as a signal that XRAY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Dentsply Sirona has launched the Primescan 2, a cloud-native intraoral scanner that enables direct scanning to the cloud via any internet-connected device, enhancing digital patient care.
Why It Matters - Dentsply Sirona's Primescan 2 enhances digital dental care, improving efficiency and patient experience, potentially driving revenue growth and increasing market competitiveness.
Fri, 06 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - XRAY has launched the Primescan 2, a new-generation intraoral scanner aimed at enhancing patient care and comfort.
Why It Matters - XRAY's launch of the Primescan 2 could enhance patient care, potentially increasing demand and revenue, impacting future earnings and stock performance positively.
Tue, 20 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - DENTSPLY SIRONA Inc. (Nasdaq: XRAY) announced the resignation of CFO Glenn Coleman, effective November 7, 2024, as he takes an executive role at another public company.
Why It Matters - Executive leadership changes can impact company stability, strategy, and financial performance, potentially affecting stock prices and investor confidence in Dentsply Sirona.
Tue, 20 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The Brazilian digital dentistry market was valued at $462 million in 2023 and is projected to grow at a CAGR of 2.9%, reaching over $564 million by 2030, with key players including Dentsply Sirona.
Why It Matters - The Brazilian digital dentistry market's projected growth reflects investment opportunities in dental tech. Key players dominate, indicating potential for mergers or market shifts, impacting stock values.
Mon, 05 Aug 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Dentsply's (XRAY) international revenue trends are influencing Wall Street's forecasts and impacting the stock's future performance.
Why It Matters - Changes in Dentsply's international revenue can influence earnings forecasts and stock valuations, affecting investment decisions and market sentiment around XRAY.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - DENTSPLY SIRONA Inc. will host its Q2 2024 earnings call on July 31, 2024, at 8:30 AM ET, featuring key executives and analysts from various firms.
Why It Matters - DENTSPLY SIRONA's Q2 2024 earnings call provides insights into financial performance, strategy, and market outlook, which are crucial for assessing investment potential and company health.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
